Celgene announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene’s proprietary IMiD medications, Revlimid (lenalidomide) and Imnovid...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok